Home › Funds › Capital International Sarl › RPRX
Capital International Sarl position in RPRX
ROYALTY PHARMA PLC · Health Care
Capital International Sarl reported holding 1,109,640 shares of RPRX (ROYALTY PHARMA PLC) in its Q3 2026 13F filing — a position valued at US$64.8M, representing 0.88% of its reported portfolio and ranking #30 among its reported holdings. Capital International Sarl has disclosed RPRX holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Capital International Sarl's RPRX position evolved
Capital International Sarl first disclosed a stake in RPRX in Q2 2025 at 324,683 shares (US$11.7M). The position peaked in Q3 2026 at 1,109,640 shares, worth US$64.8M. Across 6 filings, Capital International Sarl increased the stake 5 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,109,640 shares valued at US$64.8M — an increase of 33,577 shares quarter over quarter.. Notable position changes include a 45% increase in Q4 2025 (shares rose 24% over the following quarter), a 96% increase in Q1 2026 (shares rose 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 324.68K | $11.70M | New |
| Q3 2025 | 368.56K | $13.00M | Add |
| Q4 2025 | 534.90K | $20.67M | Add |
| Q1 2026 | 1.05M | $50.28M | Add |
| Q2 2026 | 1.08M | $60.33M | Add |
| Q3 2026 | 1.11M | $64.76M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RPRX and 13F data
RPRX (ROYALTY PHARMA PLC) is a Health Care company. 48 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$598.8M), Baillie Gifford & Co (US$534.1M), ROYAL LONDON ASSET MANAGEMENT LTD (US$348.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RPRX
- Swedbank AB 10.26M sh · $598.81M · Q3 2026
- Baillie Gifford & Co 9.15M sh · $534.11M · Q3 2026
- ROYAL LONDON ASSET MANAGEMENT LTD 5.97M sh · $348.63M · Q3 2026
- Caledonia (Private) Investments Pty Ltd 5.78M sh · $323.85M · Q2 2026
- Patient Capital Management, LLC 3.42M sh · $199.71M · Q3 2026
- Dorsey Asset Management, LLC 2.46M sh · $137.74M · Q2 2026
- Regal Partners Ltd 2.45M sh · $137.25M · Q2 2026
- HOMESTEAD ADVISERS CORP 1.66M sh · $96.68M · Q3 2026
- Clark Capital Management Group, Inc. 1.66M sh · $93.24M · Q2 2026
- NEW SOUTH CAPITAL MANAGEMENT INC 1.45M sh · $84.36M · Q3 2026
More on Capital International Sarl
FAQ
How long has Capital International Sarl held RPRX?
Capital International Sarl has disclosed RPRX holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is Capital International Sarl's current position in RPRX?
As of Q3 2026, Capital International Sarl holds 1.11M shares of RPRX (ROYALTY PHARMA PLC), valued at $64.76M, representing 0.88% of its reported portfolio and ranking #30.
Has Capital International Sarl been buying or selling RPRX?
In the latest 13F filing (Q3 2026), Capital International Sarl increased its position in RPRX. The position peaked in Q3 2026 at 1.11M shares.
Which other funds hold RPRX?
Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, ROYAL LONDON ASSET MANAGEMENT LTD, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.